In recent years, it has been found that DUXAP10 is excessively expressed in pancreatic (Lian et al., 2018) cancer (PC) tissues and cell lines (AsPC-1, BxPC-3, and PANC-1 cells), and a close correlation was observed between the overexpression of DUXAP10 and unfavorable clinicopathological characteristics, such as poor prognosis, aggressive TNM stage and lymph node metastasis. Here, DUXAP10 is linked to pachyonychia congenita.